15 July 2014

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, will announce its interim results for the six months ended 30 June 2014 on Thursday 11 September 2014.

A briefing for analysts will be held at 10.00am on the morning of the results at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.

There will be a webcast of the analyst presentation. If you would like to listen to the webcast, please log on to the following web address approximately 5 minutes before 10.00am on the day of results:

http://media.buchanan.uk.com/2014/futuramedical110914/registration.asp

A recording of the webcast will also be made available at www.futuramedical.com and www.buchanan.uk.com, following the results meeting.

For more information, or to register attendance, please contact Buchanan on 020 7466 5000.

 

For further information please contact:

Futura Medical plc
James Barder, Chief Executive
+44 (0) 1483 685 670
james.barder@futuramedical.com
www.futuramedical.com

Nominated Adviser:
N+1 Singer
Aubrey Powell / Liz Yong / Thomas Smale
Tel: +44 (0) 20 7496 3000

For media enquiries please contact:

Buchanan Communications Limited
Mark Court / Sophie Cowles /
Stephanie Watson
Tel: +44 (0) 20 7466 5000

 

Notes to Editors

Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.com